Zacks Investment Research upgraded shares of Cancer Genetics (NASDAQ:CGIX) from a sell rating to a hold rating in a report issued on Wednesday morning.
According to Zacks, “Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company’s tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey. “
A number of other research analysts have also commented on the company. HC Wainwright set a $6.00 target price on Cancer Genetics and gave the company a buy rating in a research note on Tuesday, August 15th. ValuEngine lowered Cancer Genetics from a hold rating to a sell rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $5.42.
Cancer Genetics (CGIX) opened at $2.45 on Wednesday. Cancer Genetics has a 1-year low of $1.30 and a 1-year high of $5.30. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.01 and a current ratio of 2.01.
Hedge funds and other institutional investors have recently modified their holdings of the stock. KCG Holdings Inc. acquired a new position in shares of Cancer Genetics in the first quarter valued at $102,000. Renaissance Technologies LLC raised its stake in shares of Cancer Genetics by 44.8% in the first quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock valued at $1,843,000 after purchasing an additional 139,200 shares in the last quarter. Thompson Davis & CO. Inc. raised its stake in shares of Cancer Genetics by 5,465.0% in the second quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock valued at $440,000 after purchasing an additional 109,300 shares in the last quarter. Granahan Investment Management Inc. MA raised its stake in shares of Cancer Genetics by 26.3% in the third quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after purchasing an additional 49,371 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Cancer Genetics by 61.9% in the second quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after purchasing an additional 197,619 shares in the last quarter. Institutional investors and hedge funds own 12.71% of the company’s stock.
WARNING: “Cancer Genetics (CGIX) Raised to Hold at Zacks Investment Research” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://transcriptdaily.com/2017/12/03/cancer-genetics-cgix-raised-to-hold-at-zacks-investment-research.html.
About Cancer Genetics
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cancer Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.